• MERRILL GOOZNER
• 08 Jan, 2019

Hardly a day goes by without someone in the Trump administration touting their plans to lower drug prices. No more patent games with generic drugs? Check. An easier path to biosimilars entering the market? Check. Pegging prices for office-administered drugs to international standards? Check. Actually getting something done? Check back later with us.
Read more...